Objective:

To assess the effectiveness and safety of Ofatumumab (OFA) in relapsing multiple sclerosis (RMS), specifically examining clinical, radiological, and safety outcomes, including adverse events and treatment discontinuation.

Approach:

Key Findings:

• Ofatumumab achieved substantial reductions in relapse rate and MRI activity.
• High rates of NEDA-3 were observed across treatment-naïve patients and switchers.
• Disability outcomes remained stable over follow-up with no meaningful differences across treatment subgroups.
• Prior exposure to high-efficacy therapies was the only independent predictor of infection risk under Ofatumumab.

Interpretation:

The findings suggest that Ofatumumab is effective in reducing relapse rates and MRI activity in RMS patients, regardless of prior treatment history.

Limitations:

• The study is retrospective and may be subject to biases inherent in observational studies, such as selection bias and confounding factors.
• Data were collected from a limited number of centers, which may affect generalizability to broader populations.

Conclusion:

Ofatumumab demonstrates effectiveness and safety in a real-world setting for RMS patients, with prior treatment influencing infection risk, suggesting the need for careful consideration in treatment planning.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.